Review of the current treatments for leishmaniases
Authors:
Open Access
- 1 July 2012
- journal article
- review article
- Published by Taylor & Francis in Research and Reports in Tropical Medicine
- Vol. 3, 69-77
Abstract
Leishmaniases are vector-borne zoonotic diseases that are prevalent in tropical and subtropical areas in the world, with two million new cases occurring yearly. Visceral and tegumentary forms of leishmaniasis are known. The latter form may present as localized cutaneous or mucosal forms, disseminated, diffuse forms, or leishmaniasis recidiva cutis. Visceral leishmaniasis is caused by parasites of the species Leishmania (Leishmania) donovani and L. (L.) infantum, and tegumentary leishmaniasis is caused by 15 other species, with distinct distributions in the Old and New World. The varied clinical manifestations, the multitude of Leishmania species, and the increasing incidence of HIV coinfection make the diagnosis and treatment of leishmaniases complex. Since there are no solid data relating clinical manifestations, treatment outcomes and Leishmania species the decision regarding the best therapeutic option is almost entirely based on clinical manifestations. Because most of the literature is focused on leishmaniasis in the Old World, in this review we present data on the treatment of New World leishmaniasis in more detail. Ranked therapeutic options, clinical trials, and also observations, even with a restricted number of subjects, on treatment outcome of visceral and different forms of tegumentary leishmaniasis, are presented. Treatment for leishmaniasis in HIV-coinfected patients is addressed as well. Some of these data strongly suggest that the differences in the outcome of the treatment are related to the Leishmania species. Therefore, although it is not possible at most points of care to identify the species causing the infection – a process that requires a well equipped laboratory – the infecting species should be identified whenever possible. More recent approaches, such as the use of immunomodulators and immunotherapy, and the lines for development of new candidate drugs are mentioned.Keywords
This publication has 65 references indexed in Scilit:
- New World cutaneous leishmaniasis: Updated review of current and future diagnosis and treatmentJournal of the American Academy of Dermatology, 2010
- Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, BrazilTransactions of the Royal Society of Tropical Medicine and Hygiene, 2009
- Interventions for American cutaneous and mucocutaneous leishmaniasisCochrane Database of Systematic Reviews, 2009
- Interventions for Old World cutaneous leishmaniasisCochrane Database of Systematic Reviews, 2008
- Differences in transmission seasons as an epidemiological tool for characterization of anthroponotic and zoonotic cutaneous leishmaniasis in northern AfghanistanActa Tropica, 2008
- Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin BJournal of Infection, 2005
- Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patientsActa Tropica, 2004
- Leishmaniasis: current situation and new perspectivesComparative Immunology, Microbiology and Infectious Diseases, 2004
- In VivoInterference of Paromomycin with Mitochondrial Activity ofLeishmaniaExperimental Cell Research, 1997
- Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-γ and pentavalent antimonial compoundsTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994